⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 6, 2024

Figure 3 from Phase I Study of Simlukafusp Alfa (FAP-IL2v) with or without Atezolizumab in Japanese Patients with Advanced Solid Tumors

Takafumi Koyama Kan Yonemori Toshio Shimizu Jun Sato Shunsuke Kondo Kazuki Sudo Tatsuya Yoshida Yuki Katsuya T. Imaizumi Masashi Enomoto Ryoko Seki Noboru Yamamoto

View at Publisher

Ask AI

Bookmark

Share

Abstract

Summary of efficacy with simlukafusp alfa. Best overall response in each patient is presented in parentheses at the end of the bar. NE, not evaluable; PD, progressive disease; RPC, renal pelvis cancer; SD, stable disease.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Koyama et al. (2024) studied this question.

synapsesocial.com/papers/68e59329b6db64358752e72b https://doi.org/10.1158/2767-9764.26953781

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Table 4 from Phase I Study of Simlukafusp Alfa (FAP-IL2v) with or without Atezolizumab in Japanese Patients with Advanced Solid Tumors2024
2Table 4 from Phase I Study of Simlukafusp Alfa (FAP-IL2v) with or without Atezolizumab in Japanese Patients with Advanced Solid Tumors2024
3Supplementary Figure 1 from Phase I Study of Simlukafusp Alfa (FAP-IL2v) with or without Atezolizumab in Japanese Patients with Advanced Solid Tumors2024
4Supplementary Figure 1 from Phase I Study of Simlukafusp Alfa (FAP-IL2v) with or without Atezolizumab in Japanese Patients with Advanced Solid Tumors2024
5Supplementary Figure 2 from Phase I Study of Simlukafusp Alfa (FAP-IL2v) with or without Atezolizumab in Japanese Patients with Advanced Solid Tumors2024

Supplementary Figure 2 from Phase I Study of Simlukafusp Alfa (FAP-IL2v) with or without Atezolizumab in Japanese Patients with Advanced Solid Tumors2024
Table 1 from Phase I Study of Simlukafusp Alfa (FAP-IL2v) with or without Atezolizumab in Japanese Patients with Advanced Solid Tumors2024
Table 3 from Phase I Study of Simlukafusp Alfa (FAP-IL2v) with or without Atezolizumab in Japanese Patients with Advanced Solid Tumors2024